Onyx Expects Early 2008 Launch For Nexavar In Liver Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm expects more off-label use of Nexavar in liver cancer in second half of 2007.
You may also be interested in...
Bayer Puts Marketing Muscle Behind Yaz
Company is exclusively promoting the oral contraceptive Yaz in the U.S. as it looks to drive uptake over Yasmin.
Bayer/Onyx Submit Nexavar sNDA For Liver Cancer
Filing is based on halted Phase III trial showing overall survival of 44 percent in patients with hepatocellular carcinoma treated with sorafenib.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee